Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285998 · ClinicalTrials.gov registry record · Phase 3
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
A Phase 3 study, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,003
- Enrollment target
NCT02285998: Completed Phase 3 study, sponsored by Protein Sciences Corporation.
NCT02285998 is a Phase 3 study that has completed, run by Protein Sciences Corporation. The registered enrollment target is 9,003 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1068% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02285998, a Phase 3 study, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,003 participants
- Enrollment target
Study Summary
The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age population.
Primary Outcome
rtPCR-confirmed, protocol-defined Influenza-Like Illness (ILI) caused by any influenza strain that begins at least 14 days post-vaccination
Interventions
- BIOLOGICAL Inactivated Influenza Vaccine
- BIOLOGICAL Flublok Quadrivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,003 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
What the finished NCT02285998 record still lists
NCT02285998 is an interventional study that assigns participants to a tested intervention. Its 9,003 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1068% higher).
The record links to 0 conditions, and to 2 interventions - of which Inactivated Influenza Vaccine is the first listed.
NCT02285998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02285998 about?
NCT02285998 is a clinical study titled "Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age". The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age population.
What is the current status of trial NCT02285998?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,003 participants. The study started on 2014-10. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02285998?
The interventions under investigation include: Inactivated Influenza Vaccine (BIOLOGICAL), Flublok Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02285998?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02285998's enrollment target sits among peer trials
9,003 31st of 2000 higher than 1,970 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia